Direct renin inhibition with aliskiren in hypertension and target organ damage

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Nephrology

Background:

• Hypertension remains inadequately controlled in many patients, leading to high rates of cardiovascular morbidity.
• The renin-angiotensin-aldosterone system is a key target for hypertension treatment but existing inhibitors face limitations due to compensatory increases in plasma renin.
• Novel pharmacologic approaches are needed to improve hypertension management and reduce cardiovascular complications.

Purpose of the Study:

• To evaluate the efficacy and safety of aliskiren, a direct renin inhibitor, for hypertension management.
• To assess the potential of aliskiren in providing target organ protection in a novel animal model of hypertension.
• To explore aliskiren's role in circumventing limitations associated with existing renin-angiotensin-aldosterone system inhibitors.

Main Methods:

• Clinical studies in humans to assess blood pressure-lowering effects and side effect profiles.
• Evaluation of aliskiren's efficacy in combination therapies.
• Utilisation of a novel rat model of high human renin hypertension to investigate target organ protection.

Main Results:

• Aliskiren demonstrated an effective blood pressure-lowering effect in human studies.
• The side effect profile of aliskiren was comparable to angiotensin II type 1 receptor blockers.
• The novel animal model showed that aliskiren provides target organ protection.
• Aliskiren circumvents the compensatory increase in plasma renin activity seen with other antihypertensive agents.

Conclusions:

• Aliskiren is an effective, orally administered, once-daily direct renin inhibitor for hypertension.
• Aliskiren offers a valuable therapeutic option, potentially improving outcomes by directly targeting the rate-limiting step of angiotensin production.
• Aliskiren provides a novel approach to overcome limitations of current therapies and offers potential for target organ protection.